Published in

BMJ Publishing Group, Journal for ImmunoTherapy of Cancer, S2(3), 2015

DOI: 10.1186/2051-1426-3-s2-p171

Links

Tools

Export citation

Search in Google Scholar

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC

Journal article published in 2015 by Naiyer Rizvi, Fabrice Barlesi, Julie Brahmer, Enriqueta Felip, Patrick Forde, Marina Garassino ORCID, Sarah Goldberg, Johan Vansteenkiste, Anthony Jarkowski, Stuart McIntosh, Luping Zhao, Scott Antonia
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

No abstract available.